![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 1 of 1. This is the beginning of the thread.
Posted by SalArmy4me on June 20, 2001, at 9:18:01
Well-designed studies investigating how pediatric or adolescent patients with mental disorders respond to and metabolize the newer antipsychotic drugs do exist. Clinicians should not have difficulty designing appropriate dosage regimens for patients in these age groups.
Grothe, Dale R. PharmD. "Olanzapine Pharmacokinetics in Pediatric Inpatients With Childhood-Onset Schizophrenia." Journal of Clinical Psychopharmacology. April 2000:
"...The determination of the initial olanzapine dose for adolescent patients should take into consideration factors such as the patient's size. In general, however, the usual dose recommendation of 5 to 10 mg once daily with a target dose of 10 mg/day is likely a good clinical guideline for most adolescent patients on the basis of our pharmacokinetics results..."
Horrigan, Joseph P. MD et al. "Olanzapine in PDD." Journal of Amer. Academy of Child & Adolescent Psychiatry. 36(9):1166-1167, Spt 1997:
"...In each case the olanzapine was well tolerated and was associated with a near-immediate improvement in the cluster of target behaviors. The effective dose range appeared to be similar to that demonstrated in adult populations, and the apparently benign side effect profile is consistent with the initial reports from the adult literature (Baldwin and Montgomery, 1995). These findings suggest that there may be a role for olanzapine in children with accompanying difficulties in mood and behavior..."
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.